



KINTARA

Therapeutics

Developing Advanced Oncology Therapies for Rare Unmet Medical Needs

Corporate Presentation

March 2024

Forward Looking Statements

This presentation contains forward-looking statements based upon Kintara’s current expectations. This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar words. These statements are only predictions. Kintara has based these forward-looking statements largely on its then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Kintara’s control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) risks associated with the impact of the COVID-19 pandemic; (ii) risks and uncertainties relating to Kintara’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of Kintara’s products and technology; the availability of substantial additional funding for Kintara to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, Kintara’s business, research, product development, regulatory approval, marketing and distribution plans and strategies, and (iii) those risks detailed in Kintara’s most recent Annual Report on Form 10-K and subsequent reports filed with the SEC, as well as other documents that may be filed by Kintara from time to time with the SEC. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Kintara cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. Except as required by applicable law or regulation, Kintara undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. Investors should not assume that any lack of update to a previously issued “forward-looking statement” constitutes a reaffirmation of that statement.

Late-stage Oncology Company De-Risked Product Candidate

REM-001: 2nd generation photodynamic therapy platform


- National Institutes of Health grant awarded June 2023
- 15-patient confirmatory study initiated February 2024
- ~\$500M² market in lead program: Cutaneous Metastatic Breast Cancer (CMBC)
- Fast Track Designation Granted from FDA in CMBC Patients in November 2022
- Extensive Phase 2/Phase 3 efficacy data (80% complete responses across four trials)
- Over 1,100 patient safety database
- Additional indications include Recurrent Basal Cell Carcinoma Nevus Syndrome (Orphan Drug Designation from FDA)

¹GlobalData November 2018

²Charles River Associates April 2018

REM-001: 2nd Generation Photodynamic Cancer Therapy

CMBC Overview



Cutaneous Metastatic Breast Cancer is a major unmet medical need
National Institutes of Health Grant awarded in June 2023

Up to 40,000 patients in the U.S.¹, representing \$500M market opportunity²

Clinical aspects: Highly morbid form of breast cancer

- Bleeding, infectious and malodorous lesions on chest wall, neck and back
- Narcotics for pain control


Limited current therapies

- Chemotherapy: generally non-responsive
- Radiation: dose limiting toxicities, lesions are often refractory to radiation




¹Source (a): Saika et al, 2009; Kamaraju et al, 2016; Vano-Galvan et al, 2009; GlobalData Report on Metastatic Breast Cancer; Schoenlaub et al, 2001

²Charles River Report April 2018


Photodynamic Therapy Mechanisms of Action



PDT induces elimination of diseased cells by immune response, apoptosis, antiangiogenesis and necrosis



REM-001: High Response Rates in CMBC



Second Generation Photodynamic Therapy

- Light activated cancer therapy

Extensive data from prior Phase 2/Phase 3 clinical trials

- 149 patients treated in 4 trials
 - 80% complete response rate in 674 evaluable lesions

Localized Outpatient Treatment

- IV drug infusion accumulates in tumors
- Activated by simple red light

Safety database ~1,100 patients

Previous trial experience used to optimize current trial design

REM-001: CMBC Development Plan

Development plan optimized for success while minimizing cost

- Phase 3 ready
- 15-patient open label study to confirm lower dose and optimize trial design initiated February 2024
- Leverages prior data indicating lower dose can improve outcome
 - Faster healing
 - Less photosensitivity
- De-risks full Phase 3 study

IND reactivated August 2022

Fast Track designation received from the FDA in November 2022

National Institutes of Health Grant awarded June 2023

Indication Expansion Opportunities

REM-001

- Other Cutaneous Metastatic Cancers
- Recurrent Basal Cell Carcinoma Nevus Syndrome¹
- Locally Advanced Basal Cell Carcinoma (laBCC)
- Peripheral Lung Cancer
- Hemodialysis Arteriovenous (AV) Access

¹*Demonstrated positive results in prior sponsor's Phase 2 study*

REM-001 Barriers to Competition

New Chemical Entity

- Five years data exclusivity after approval in US
- 8+2+1 Regime in Europe

Combination Product Regulatory Pathway

- REM-001 and Laser Device

Follow-on Indication Orphan Drug Designations in US

- Basal cell carcinoma nevus syndrome (BCCNS)
- Hemodialysis access grafts

CEO Biography

Robert Hoffman

President and CEO
Chair, Board of
Directors

CEO of Kintara from November 2021, Chair of Board from June 2018; Board member of ASLAN Pharmaceuticals and Antibe Therapeutics; previously served as Senior Vice President and Chief Financial Officer of Heron Therapeutics from April 2017 to October 2020; part of the founding management team of Arena Pharmaceuticals in 1997, serving in various roles until 2015, including Senior Vice President, Finance and Chief Financial Officer

Investment Highlights

- Late-stage oncology company with highly de-risked for underserved indications
- REM-001 — Light activated cancer therapy diversifies late-stage oncology pipeline
 - 80% complete responses across four clinical trials to date in CMBC
 - 15-Patient confirmatory study initiated February 2024
 - National Institutes of Health grant awarded to support 15-Patient study
 - \$500M market opportunity¹
- Upcoming milestone/value inflection event
 - Reporting on patients in open label 15-Patient confirmatory study
- Evaluating other assets to in-license/strategic alternatives
 - Clean capitalization structure
 - No debt
 - Nasdaq capital markets listing
 - Strengthened Balance Sheet by utilizing ATM facility

¹Charles River Associates April 2018